Analyses / JNJ
Large-cap pharma at 52-week highs; premium valuation offset by quality, dividends, low beta.
A free account reveals JNJ's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
JNJ trades near 52-week highs ($263.1) on +3.6% daily move. Forward P/E 23.4x is reasonable for 17.9% EPS growth and 34.6% operating margins. Dividend yield 2.1% + payout ratio 46% offer income + reinvestment runway. Ultra-low beta (0.22) provides portfolio ballast. Congress insiders accumulating signals confidence. Gross margin 68% and net margin 28% reflect pricing power and scale.
▼ Bear Case
Trailing P/E 29.8x is elevated vs. S&P 500 (~19–21x). Price-to-FCF 31.8x signals expensive cash generation relative to price. P/B 6.1x and P/S 6.7x above historical norms. Revenue growth slowing to 5.6% YoY (2.67% 5Y CAGR) indicates mature, slow-growth trajectory. Insider selling (135 sells vs. 120 buys) slightly net-negative. Quick ratio 0.69 shows tight near-term liquidity; must rely on cash generation.
Valuation
overvalued — score 58/100
Trailing P/E 29.8x is premium to S&P 500 median (~19–21x); forward P/E 23.4x is more reasonable but still above historical JNJ average (~20–21x). P/S 6.7x and P/B 6.1x elevated. However, quality (margins 28–68%), low beta, and dividend yield (2.1%) justify modest premium. Thesis: fairly to slightly overvalued; suitable for quality-seeking, low-volatility portfolios, not deep-value buyers.
Technical Levels
Support · $254.00 (Today's intraday low) · $255.78 (Today's open) · $253.98 (Previous close) · $240.00 (Estimated 52-week support zone)
Resistance · $263.10 (52-week high / today's high) · $270.00 (Psychological / next resistance) · $280.00 (Medium-term target zone)
RSI: Not provided in Finnhub payload
Financial Health
Score 78/100. Solid balance sheet with high margins and sustainable dividend. Quick ratio (0.69) indicates reliance on cash generation and receivables turnover; not alarming for a large, stable pharma. Payout ratio 46% leaves room for growth. No debt-to-equity provided; assume manageable given credit profile.
Risk Flags
See JNJ's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock JNJ free →Recent News
- Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here's Why Retail Investors Should Pay Attention.Yahoo
- Sector Update: Healthcare Stocks Gain Late AfternoonYahoo
- Which dow jones stocks are moving on Thursday?ChartMill
- The Portfolio That Pays For Season Tickets ForeverYahoo
- How Much Capital Does It Take to Fund Your Hobby Forever?Yahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full JNJ analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
JNJ FAQ
Is JNJ a buy right now?
Johnson & Johnson's current read is a Quality Dividend / Defensive Value setup with 68 confidence over a 6–12 months horizon. Valuation: overvalued. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is JNJ overvalued?
overvalued (valuation score 58/100). Trailing P/E 29.8x is premium to S&P 500 median (~19–21x); forward P/E 23.4x is more reasonable but still above historical JNJ average (~20–21x). P/S 6.7x and P/B 6.1x elevated. However, quality (margins 28–68%), low beta, and dividend yield (2.1%) justify modest premium. Thesis: fairly to slightly overvalued; suitable for quality-seeking, low-volatility portfolios, not deep-value buyers.
What are the risks of buying JNJ?
Trailing P/E 29.8x is elevated vs. S&P 500 (~19–21x). Price-to-FCF 31.8x signals expensive cash generation relative to price. P/B 6.1x and P/S 6.7x above historical norms. Revenue growth slowing to 5.6% YoY (2.67% 5Y CAGR) indicates mature, slow-growth trajectory. Insider selling (135 sells vs. 120 buys) slightly net-negative. Quick ratio 0.69 shows tight near-term liquidity; must rely on cash generation.